Commodore Capital LP Makes New $9.33 Million Investment in Contineum Therapeutics, Inc. $CTNM

Posted by Stanley Muller on Jun 18th, 2026

Commodore Capital LP acquired a new position in Contineum Therapeutics, Inc. (NASDAQ:CTNM – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 816,326 shares of the company’s stock, valued at approximately $9,331,000. Contineum Therapeutics accounts for approximately 0.6% of Commodore Capital LP’s portfolio, making the stock its 29th largest holding. Commodore Capital LP owned approximately 2.80% of Contineum Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC raised its stake in Contineum Therapeutics by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 213,869 shares of the company’s stock valued at $2,446,000 after acquiring an additional 2,819 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Contineum Therapeutics in the fourth quarter worth $43,000. Strs Ohio acquired a new position in shares of Contineum Therapeutics during the first quarter valued at $27,000. Schonfeld Strategic Advisors LLC raised its stake in shares of Contineum Therapeutics by 22.6% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 22,673 shares of the company’s stock valued at $259,000 after purchasing an additional 4,177 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in Contineum Therapeutics by 500.0% in the third quarter. Bank of America Corp DE now owns 7,236 shares of the company’s stock worth $85,000 after purchasing an additional 6,030 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Wall Street Zen raised shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Monday, April 20th. Robert W. Baird boosted their target price on Contineum Therapeutics from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Friday, March 6th. Finally, Morgan Stanley upped their target price on Contineum Therapeutics from $14.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $20.00.

Read Our Latest Research Report on CTNM

Contineum Therapeutics Price Performance

NASDAQ CTNM opened at $12.16 on Thursday. Contineum Therapeutics, Inc. has a 12 month low of $3.57 and a 12 month high of $16.33. The company has a market capitalization of $454.66 million, a P/E ratio of -6.24 and a beta of 0.89. The company’s 50 day simple moving average is $13.04 and its 200 day simple moving average is $12.99.

Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.16. On average, analysts anticipate that Contineum Therapeutics, Inc. will post -1.68 earnings per share for the current year.

About Contineum Therapeutics

(Free Report)

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.